Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest Chinese Drug Coverage Comes With Steep Price Cuts, Caveats

But Bigger Volumes Await

Executive Summary

November negotiations in China over the prices of 67 new drugs have resulted in record price cuts, averaging around 62% overall and 65% for anti-tumor products. But the sting is alleviated by the prospect of substantial volume increases.

You may also be interested in...



Balancing Act: Orphan Drug Makers Slash Prices In China As New Mechanism Allures

From Biogen to Takeda, multinationals have been cutting prices in China in a bid to seize the emerging market for rare disease treatments, as Beijing strives to expand market access.

Rare Chance Or Passing Opportunity: China Expands Orphan Drug Coverage With Steep Price Cuts

Latest national medical insurance negotiations results show orphan drugs are covered, but Biogen’s Spinraza gets a 95% price cut. Getting coverage, rather holding out for a high price, really makes more sense in the emerging Chinese market for rare disease drugs, industry observers say.

Venture Investors See China Remaining Attractive Despite High Valuations

In a vote of confidence, investors predict Shanghai IPOs to rise in 2022, while sluggish share performances in Hong Kong have made a public listing there more “a liquidity rather than an exit event.”

Topics

Related Companies

UsernamePublicRestriction

Register

SC145531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel